Daniel Faga - Net Worth and Insider Trading

Daniel Faga Net Worth

The estimated net worth of Daniel Faga is at least $29 Million dollars as of 2026-09-11. Daniel Faga is the President, CEO of AnaptysBio Inc and owns about 495,965 shares of AnaptysBio Inc (ANAB) stock worth over $27 Million. Daniel Faga is the EVP, COO of Mirati Therapeutics Inc and owns about 30,638 shares of Mirati Therapeutics Inc (MRTX) stock worth over $2 Million. Daniel Faga is also the Chief Business Officer of Spark Therapeutics Inc and owns about 0 shares of Spark Therapeutics Inc (ONCE) stock worth over $0. Details can be seen in Daniel Faga's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daniel Faga has not made any transactions after 2026-03-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Daniel Faga

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

ANAB AnaptysBio Inc

94% of holdings · $27.6M

MRTX Mirati Therapeutics Inc

6% of holdings · $1.8M

ONCE Spark Therapeutics Inc

Daniel Faga Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Daniel Faga owns 4 companies in total, including Mirati Therapeutics Inc (MRTX) , Spark Therapeutics Inc (ONCE) , and AnaptysBio Inc (ANAB) among others .

Click here to see the complete history of Daniel Faga’s form 4 insider trades.

Insider Ownership Summary of Daniel Faga

Ticker	Company	Transaction Date	Type of Owner
MRTX	Mirati Therapeutics Inc	2021-02-02	EVP & Chief Operating Officer
ONCE	Spark Therapeutics Inc	2019-12-17	Chief Business Officer
ANAB	AnaptysBio Inc	2026-03-27	director
		2026-04-01	director & President & CEO

Daniel Faga Latest Holdings Summary

Daniel Faga currently owns a total of 3 stocks. Among these stocks, Daniel Faga owns 495,965 shares of AnaptysBio Inc (ANAB) as of March 27, 2026, with a value of $27 Million and a weighting of 93.83%. Daniel Faga owns 30,638 shares of Mirati Therapeutics Inc (MRTX) as of February 2, 2021, with a value of $2 Million and a weighting of 6.17%. Daniel Faga also owns 0 shares of Spark Therapeutics Inc (ONCE) as of October 24, 2017, with a value of $0 and a weighting of 0%.

Latest Holdings of Daniel Faga

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ANAB	AnaptysBio Inc	2026-03-27	495,965	55.13	27,342,550
MRTX	Mirati Therapeutics Inc	2021-02-02	30,638	58.70	1,798,451
ONCE	Spark Therapeutics Inc	2017-10-24	0	113.57	0

Holding Weightings of Daniel Faga

Daniel Faga Form 4 Trading Tracker

According to the SEC Form 4 filings, Daniel Faga has made a total of 6 transactions in AnaptysBio Inc (ANAB) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in AnaptysBio Inc is the sale of 17,679 shares on March 27, 2026, which brought Daniel Faga around $1 Million.

According to the SEC Form 4 filings, Daniel Faga has made a total of 0 transactions in Mirati Therapeutics Inc (MRTX) over the past 5 years. The most-recent trade in Mirati Therapeutics Inc is the sale of 1,340 shares on February 2, 2021, which brought Daniel Faga around $260,469.

According to the SEC Form 4 filings, Daniel Faga has made a total of 0 transactions in Spark Therapeutics Inc (ONCE) over the past 5 years. The most-recent trade in Spark Therapeutics Inc is the sale of 7,500 shares on October 24, 2017, which brought Daniel Faga around $607,200.

Insider Trading History of Daniel Faga

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Daniel Faga Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Daniel Faga owns.

- ANAB - MRTX - ONCE

View ANAB Analysis

Daniel Faga Ownership Network

Ownership Network List of Daniel Faga

No Data

Ownership Network Relation of Daniel Faga

Daniel Faga Owned Company Details

What does Mirati Therapeutics Inc do?

Who are the key executives at Mirati Therapeutics Inc?

Daniel Faga is the EVP & Chief Operating Officer of Mirati Therapeutics Inc. Other key executives at Mirati Therapeutics Inc include Sr. Vice President & Chief Scie Jamie Christensen , EVP & Chief Commercial Officer Benjamin Hickey , and Interim CFO Aaron Ondrey .

Mirati Therapeutics Inc (MRTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Mirati Therapeutics Inc (MRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Mirati Therapeutics Inc (MRTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Mirati Therapeutics Inc (MRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mirati Therapeutics Inc Insider Transactions

No Available Data

What does Spark Therapeutics Inc do?

Who are the key executives at Spark Therapeutics Inc?

Daniel Faga is the Chief Business Officer of Spark Therapeutics Inc. Other key executives at Spark Therapeutics Inc include director & See Remarks Katherine A High , 10 percent owner Roche Holding Ltd , and director & CHIEF SCIENTIFIC OFFICER Lota S. Zoth .

Spark Therapeutics Inc (ONCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Spark Therapeutics Inc (ONCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Spark Therapeutics Inc (ONCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Spark Therapeutics Inc (ONCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Spark Therapeutics Inc Insider Transactions

No Available Data

What does AnaptysBio Inc do?

Who are the key executives at AnaptysBio Inc?

Daniel Faga is the director of AnaptysBio Inc. Other key executives at AnaptysBio Inc include Chief Financial Officer Christopher M. Murphy , General Counsel Eric J Loumeau , and Chief Medical Officer Paul F. Lizzul .

AnaptysBio Inc (ANAB) Insider Trades Summary

Over the past 18 months, Daniel Faga made 4 insider transaction in AnaptysBio Inc (ANAB) with a net sale of 56,471. Other recent insider transactions involving AnaptysBio Inc (ANAB) include a net sale of 65,713 shares made by Eric J Loumeau , a net sale of 33,511 shares made by Dennis Mulroy , and a net sale of 11,604 shares made by Paul F. Lizzul .

In summary, during the past 3 months, insiders sold 0 shares of AnaptysBio Inc (ANAB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 240,030 shares of AnaptysBio Inc (ANAB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 240,030 shares.

AnaptysBio Inc (ANAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

AnaptysBio Inc Insider Transactions

No Available Data

What does First Tracks Biotherapeutics Inc do?

Who are the key executives at First Tracks Biotherapeutics Inc?

Daniel Faga is the director & President & CEO of First Tracks Biotherapeutics Inc. Other key executives at First Tracks Biotherapeutics Inc include 10 percent owner Ecor1 Capital, Llc , Chief Business Officer Benjamin Stone , and Chief Financial Officer Ajim Tamboli .

First Tracks Biotherapeutics Inc (TRAX) Insider Trades Summary

Over the past 18 months, Daniel Faga made no insider transaction in First Tracks Biotherapeutics Inc (TRAX). Other recent insider transactions involving First Tracks Biotherapeutics Inc (TRAX) include a net sale of 4,705,575 shares made by Ecor1 Capital, Llc , and a net sale of 39,265 shares made by J. Anthony Ware .

In summary, during the past 3 months, insiders sold 39,265 shares of First Tracks Biotherapeutics Inc (TRAX) in total and bought 0 shares, with a net sale of 39,265 shares. During the past 18 months, 4,744,840 shares of First Tracks Biotherapeutics Inc (TRAX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,744,840 shares.

First Tracks Biotherapeutics Inc (TRAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

First Tracks Biotherapeutics Inc Insider Transactions

No Available Data

Daniel Faga Mailing Address

Above is the net worth, insider trading, and ownership report for Daniel Faga. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Daniel Faga's mailing address is: Philadelphia Pa 19104.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.